NO955352D0 - Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse - Google Patents

Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse

Info

Publication number
NO955352D0
NO955352D0 NO955352A NO955352A NO955352D0 NO 955352 D0 NO955352 D0 NO 955352D0 NO 955352 A NO955352 A NO 955352A NO 955352 A NO955352 A NO 955352A NO 955352 D0 NO955352 D0 NO 955352D0
Authority
NO
Norway
Prior art keywords
preparation
pct
acid ester
phosphoric acid
methyl phosphoric
Prior art date
Application number
NO955352A
Other languages
English (en)
Other versions
NO955352L (no
NO319860B1 (no
Inventor
Eugen Uhlmann
Chris Meier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO955352D0 publication Critical patent/NO955352D0/no
Publication of NO955352L publication Critical patent/NO955352L/no
Publication of NO319860B1 publication Critical patent/NO319860B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19955352A 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse NO319860B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4321946A DE4321946A1 (de) 1993-07-01 1993-07-01 Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP1994/002121 WO1995001363A1 (de) 1993-07-01 1994-06-29 Methylphosphonsäureester, verfahren zu deren herstellung und deren verwendung

Publications (3)

Publication Number Publication Date
NO955352D0 true NO955352D0 (no) 1995-12-29
NO955352L NO955352L (no) 1996-02-14
NO319860B1 NO319860B1 (no) 2005-09-26

Family

ID=6491730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19955352A NO319860B1 (no) 1993-07-01 1995-12-29 Metylfosfonsyre-ester, fremgangsmate for fremstilling, legemiddel samt anvendelse

Country Status (13)

Country Link
US (1) US6028182A (no)
EP (1) EP0707591B1 (no)
JP (1) JP3831407B2 (no)
AT (1) ATE206130T1 (no)
AU (1) AU698928B2 (no)
CA (1) CA2165971C (no)
DE (2) DE4321946A1 (no)
DK (1) DK0707591T3 (no)
ES (1) ES2165391T3 (no)
FI (1) FI115399B (no)
NO (1) NO319860B1 (no)
PT (1) PT707591E (no)
WO (1) WO1995001363A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
PT739898E (pt) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
DE69736840T2 (de) * 1996-12-24 2007-08-09 Sirna Therapeutics, Inc., Boulder Synthese von nukleosiden und polynukleotiden
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
WO2002066092A2 (en) * 2001-02-23 2002-08-29 Angiogene Inc. Drug eluting device for treating vascular diseases
GB0110732D0 (en) * 2001-05-02 2001-06-27 Psl Technology Ltd Apparatus and method
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
US20050256073A1 (en) 2004-02-19 2005-11-17 Coley Pharmaceutical Group, Inc. Immunostimulatory viral RNA oligonucleotides
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
DK1991678T4 (da) 2006-02-15 2020-10-19 Rechtsanwalt Thomas Beck Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
KR101251707B1 (ko) 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
WO2008142509A2 (en) * 2007-05-17 2008-11-27 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
KR20100068422A (ko) 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
EP2306986B1 (en) * 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
MY160201A (en) 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
IN2012DN00446A (no) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
BR112012030337B1 (pt) 2010-05-28 2021-04-27 Coley Pharmaceutical Group, Inc Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
LT3240801T (lt) 2014-12-31 2021-02-25 Checkmate Pharmaceuticals, Inc. Kombinuota navikų imunoterapija
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
MX2020010410A (es) 2018-04-09 2021-01-15 Checkmate Pharmaceuticals Empaquetado de oligonucleotidos en particulas similares a virus.
WO2024127215A2 (en) 2022-12-13 2024-06-20 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025238502A1 (en) 2024-05-14 2025-11-20 Pfizer Inc. Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010140A1 (en) * 1991-11-21 1993-05-27 Pharmagenics, Inc. Oligonucleotides having modified anionic moieties

Also Published As

Publication number Publication date
JP3831407B2 (ja) 2006-10-11
CA2165971A1 (en) 1995-01-12
US6028182A (en) 2000-02-22
WO1995001363A1 (de) 1995-01-12
EP0707591B1 (de) 2001-09-26
AU698928B2 (en) 1998-11-12
DK0707591T3 (da) 2002-01-21
ATE206130T1 (de) 2001-10-15
CA2165971C (en) 2006-05-30
ES2165391T3 (es) 2002-03-16
EP0707591A1 (de) 1996-04-24
JPH08512039A (ja) 1996-12-17
DE59409880D1 (de) 2001-10-31
FI956341A0 (fi) 1995-12-29
PT707591E (pt) 2002-03-28
AU7073594A (en) 1995-01-24
FI956341L (fi) 1996-02-19
FI115399B (fi) 2005-04-29
NO955352L (no) 1996-02-14
NO319860B1 (no) 2005-09-26
DE4321946A1 (de) 1995-01-12

Similar Documents

Publication Publication Date Title
NO955352L (no) Metylfosforsyreester, fremgangsmåte for fremstilling samt anvendelse
AU699480B2 (en) 2,2-Dichloroalkane carboxylic acids, processes for their production and pharmaceutical agents containing these
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
HU9603592D0 (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
EP0948327A4 (en) ANTIDIABETIC AGENTS
IT1270260B (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
WO2000071516A3 (en) INHIBITORS OF FACTOR Xa
PL300328A1 (en) Substituted cyclohexane derivatives for treating diseases
WO2001091738A3 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
AU686197B2 (en) Use of coumarins and carbostyrils as PLA2-inhibitors, new coumarins and carbostyrils, process for preparing the same and medicaments
BR9408244A (pt) Derivados de azabiciclo[3.2.0]heptano N-substituídos
TW261614B (no)
IL107520A0 (en) Substituted ortho-ethenylphenylacetic acid derivatives and pharmaceutical compositions containing them
EP0653206A4 (en) ANTI-HIV ACTIVE SUBSTANCE.
PL355763A1 (en) Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same